Peptide record

TPDB07027

Antibacterial Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07027
Antibacterial Toxicity
Anti-infective peptides Toxicity and safety peptides
AntiBP3 Peptipedia
standard
No
A 13-aa standard natural multi-activity (Antibacterial and Toxicity) peptide sequence curated from AntiBP3 and Peptipedia, with an available 3D structural model.
Sequence
IKKWWSKIKKLLK
Physicochemical Analysis
C85H143N21O15
ARNDCEQGHMFPTYV
K
1699.20
11.21
6
0
6
+6
0.63
-0.723
120.00
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
11000
647.36
1
Residue Composition
number
0
A
0
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
2
I
2
L
6
K
0
M
0
F
0
P
1
S
0
T
2
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 2 L: 2 K: 6 M: 0 F: 0 P: 0 S: 1 T: 0 W: 2 Y: 0 V: 0
Chemical Descriptors
13
C85H143N21O15
1699.20
11.21
+6
0.63
-0.723
Evidence Records 3 records
Evidence 1 Activity

Activity

50% Hemolysis
Toxicity
>500 µM
Hemolytic Cytotoxic
50% Hemolysis | >500 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial properties and interaction of two Trp-substituted cationic antimicrobial peptides with a lipid bilayer. | J Antibiot (Tokyo) | 2014
Evidence 2 Activity

Activity

<1% Hemolysis
Toxicity
0.78 µM
Hemolytic Cytotoxic
<1% Hemolysis | 0.78 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Synergistic Antibacterial Activity of Designed Trp-Containing Antibacterial Peptides in Combination With Antibiotics Against Multidrug-Resistant Staphylococcus epidermidis. | Front Microbiol | 2019
Evidence 3 Activity

Activity

10% Killing
Toxicity
0.78 µM
Cytotoxic
10% Killing | 0.78 | µM | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
Synergistic Antibacterial Activity of Designed Trp-Containing Antibacterial Peptides in Combination With Antibiotics Against Multidrug-Resistant Staphylococcus epidermidis. | Front Microbiol | 2019